Regel Therapeutics, a next-generation gene therapy company utilizing proprietary technology to modulate gene expression, today announced that based upon the groundbreaking work of its Co-Founder and Chief Scientific Officer Dr. Navneet Matharu it has been selected to receive $1 Million in non-dilutive funding from the HS Chau Foundation through the Women in Enterprising Science Program (WIES) at the Innovative Genomics Institute (IGI) founded by CRISPR pioneer and Nobel laureate Dr. Jennifer Doudna.
Nadav Ahituv, PhD is the lead UCSF contributor to the technology and an ongoing advisor to Regal Therapeutics. Congratulations to all.